BRPI0610048A2

BRPI0610048A2 - terapia de combinação que compreende um composto de diaril uréia e uma pi3, akt quinase ou inibidores de mtor (rapamicinas) para o tratamento de cáncer

terapia de combinação que compreende um composto de diaril uréia e uma pi3, akt quinase ou inibidores de mtor (rapamicinas) para o tratamento de cáncer Download PDF

Info

Publication number: BRPI0610048A2
Authority: BR; Brazil
Prior art keywords: formula; cancer; compound; rapamycin; akt
Prior art date: 2005-05-27

Application number

BRPI0610048-1A

Other languages

English (en)

Portuguese (pt)

Inventor

Urban Scheuring

Ingo Bernard

Original Assignee

Bayer Healthcare Ag

Priority date

2005-05-27

Filing date

2006-05-13

Publication date

2010-05-25

2006-05-13 Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag

2010-05-25 Publication of BRPI0610048A2 publication Critical patent/BRPI0610048A2/pt

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 63
201000011510 cancer Diseases 0.000 title claims abstract description 39
-1 diaryl urea compound Chemical class 0.000 title claims abstract description 35
239000003112 inhibitor Substances 0.000 title claims abstract description 33
108091008611 Protein Kinase B Proteins 0.000 title claims abstract description 26
229960002930 sirolimus Drugs 0.000 title claims abstract description 15
238000011282 treatment Methods 0.000 title claims abstract description 13
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title claims abstract description 10
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title claims abstract description 9
239000004202 carbamide Substances 0.000 title abstract description 4
238000002648 combination therapy Methods 0.000 title abstract 2
101150097381 Mtor gene Proteins 0.000 title description 2
230000007730 Akt signaling Effects 0.000 claims abstract description 20
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims abstract description 5
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims abstract description 5
229960005167 everolimus Drugs 0.000 claims abstract description 5
229960000235 temsirolimus Drugs 0.000 claims abstract description 5
HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 claims abstract description 5
229940124302 mTOR inhibitor Drugs 0.000 claims abstract description 4
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims abstract description 4
229950003873 triciribine Drugs 0.000 claims abstract description 4
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims abstract description 3
229960000590 celecoxib Drugs 0.000 claims abstract description 3
229940043355 kinase inhibitor Drugs 0.000 claims abstract description 3
239000003757 phosphotransferase inhibitor Substances 0.000 claims abstract description 3
QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 103
238000000034 method Methods 0.000 claims description 29
150000003839 salts Chemical class 0.000 claims description 25
QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical class C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims description 10
206010006187 Breast cancer Diseases 0.000 claims description 9
208000026310 Breast neoplasm Diseases 0.000 claims description 9
201000001441 melanoma Diseases 0.000 claims description 9
QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims description 9
229940002612 prodrug Drugs 0.000 claims description 8
239000000651 prodrug Substances 0.000 claims description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
150000002148 esters Chemical class 0.000 claims description 6
206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
206010060862 Prostate cancer Diseases 0.000 claims description 5
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
239000012453 solvate Substances 0.000 claims description 5
BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims description 4
206010033128 Ovarian cancer Diseases 0.000 claims description 4
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 4
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
239000002207 metabolite Substances 0.000 claims description 4
201000002528 pancreatic cancer Diseases 0.000 claims description 4
208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
229960001302 ridaforolimus Drugs 0.000 claims description 4
102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims description 3
208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 3
208000014018 liver neoplasm Diseases 0.000 claims description 3
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 2
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 2
YULUCECVQOCQFQ-UHFFFAOYSA-N OSU-03012 Chemical compound C1=CC(NC(=O)CN)=CC=C1N1C(C=2C=C3C(C4=CC=CC=C4C=C3)=CC=2)=CC(C(F)(F)F)=N1 YULUCECVQOCQFQ-UHFFFAOYSA-N 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
125000004104 aryloxy group Chemical group 0.000 claims description 2
210000000481 breast Anatomy 0.000 claims description 2
125000005842 heteroatom Chemical group 0.000 claims description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
QFMKPDZCOKCBAQ-NFCVMBANSA-N sar943-nxa Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)CC1 QFMKPDZCOKCBAQ-NFCVMBANSA-N 0.000 claims description 2
230000002195 synergetic effect Effects 0.000 claims description 2
125000003831 tetrazolyl group Chemical group 0.000 claims description 2
206010009944 Colon cancer Diseases 0.000 claims 2
208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
IVYPNXXAYMYVSP-UHFFFAOYSA-N Indole-3-carbinol Natural products C1=CC=C2C(CO)=CNC2=C1 IVYPNXXAYMYVSP-UHFFFAOYSA-N 0.000 claims 1
RUMVKBSXRDGBGO-UHFFFAOYSA-N indole-3-carbinol Chemical compound C1=CC=C[C]2C(CO)=CN=C21 RUMVKBSXRDGBGO-UHFFFAOYSA-N 0.000 claims 1
235000002279 indole-3-carbinol Nutrition 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
150000003905 phosphatidylinositols Chemical class 0.000 claims 1
125000004076 pyridyl group Chemical group 0.000 claims 1
102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 abstract description 20
108091007960 PI3Ks Proteins 0.000 abstract description 14
230000019491 signal transduction Effects 0.000 abstract description 9
102000038030 PI3Ks Human genes 0.000 abstract description 3
239000008194 pharmaceutical composition Substances 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 46
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 37
201000010099 disease Diseases 0.000 description 28
230000000694 effects Effects 0.000 description 28
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
230000033115 angiogenesis Effects 0.000 description 20
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
238000012360 testing method Methods 0.000 description 14
238000003556 assay Methods 0.000 description 13
239000000758 substrate Substances 0.000 description 13
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 12
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 12
239000000872 buffer Substances 0.000 description 12
229940079593 drug Drugs 0.000 description 12
239000003814 drug Substances 0.000 description 12
230000037361 pathway Effects 0.000 description 12
230000001225 therapeutic effect Effects 0.000 description 12
208000015181 infectious disease Diseases 0.000 description 10
102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
239000000890 drug combination Substances 0.000 description 9
101100342473 Drosophila melanogaster Raf gene Proteins 0.000 description 8
101100523543 Rattus norvegicus Raf1 gene Proteins 0.000 description 8
101100523549 Xenopus laevis raf1 gene Proteins 0.000 description 8
101150037250 Zhx2 gene Proteins 0.000 description 8
239000013543 active substance Substances 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
239000000203 mixture Substances 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 7
230000004663 cell proliferation Effects 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 6
206010061218 Inflammation Diseases 0.000 description 6
102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 6
108010011536 PTEN Phosphohydrolase Proteins 0.000 description 6
102000014160 PTEN Phosphohydrolase Human genes 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
108091000080 Phosphotransferase Proteins 0.000 description 6
108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 6
239000002253 acid Substances 0.000 description 6
230000012010 growth Effects 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
230000035772 mutation Effects 0.000 description 6
102000020233 phosphotransferase Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
208000037803 restenosis Diseases 0.000 description 6
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
239000007995 HEPES buffer Substances 0.000 description 5
206010039491 Sarcoma Diseases 0.000 description 5
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 5
239000002585 base Substances 0.000 description 5
210000004204 blood vessel Anatomy 0.000 description 5
210000003711 chorioallantoic membrane Anatomy 0.000 description 5
230000003511 endothelial effect Effects 0.000 description 5
239000003102 growth factor Substances 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
238000004020 luminiscence type Methods 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
230000026731 phosphorylation Effects 0.000 description 5
238000006366 phosphorylation reaction Methods 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
206010027476 Metastases Diseases 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
102000001253 Protein Kinase Human genes 0.000 description 4
201000004681 Psoriasis Diseases 0.000 description 4
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
208000019425 cirrhosis of liver Diseases 0.000 description 4
210000001072 colon Anatomy 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
210000002889 endothelial cell Anatomy 0.000 description 4
231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
230000002519 immonomodulatory effect Effects 0.000 description 4
230000009401 metastasis Effects 0.000 description 4
150000007522 mineralic acids Chemical class 0.000 description 4
201000006417 multiple sclerosis Diseases 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
108060006633 protein kinase Proteins 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
201000001320 Atherosclerosis Diseases 0.000 description 3
206010012689 Diabetic retinopathy Diseases 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
206010016654 Fibrosis Diseases 0.000 description 3
206010018364 Glomerulonephritis Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
208000017604 Hodgkin disease Diseases 0.000 description 3
208000010747 Hodgkins lymphoma Diseases 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 3
208000017442 Retinal disease Diseases 0.000 description 3
206010038923 Retinopathy Diseases 0.000 description 3
206010040047 Sepsis Diseases 0.000 description 3
206010040070 Septic Shock Diseases 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
229920004890 Triton X-100 Polymers 0.000 description 3
239000013504 Triton X-100 Substances 0.000 description 3
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
229910000147 aluminium phosphate Inorganic materials 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
238000001516 cell proliferation assay Methods 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
230000006870 function Effects 0.000 description 3
208000014829 head and neck neoplasm Diseases 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
208000014674 injury Diseases 0.000 description 3
238000000021 kinase assay Methods 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000010232 migration assay Methods 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
241000701447 unidentified baculovirus Species 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
206010001935 American trypanosomiasis Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010003571 Astrocytoma Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
206010005003 Bladder cancer Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
208000024699 Chagas disease Diseases 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 2
101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
201000009273 Endometriosis Diseases 0.000 description 2
208000010412 Glaucoma Diseases 0.000 description 2
241000589989 Helicobacter Species 0.000 description 2
101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
208000019693 Lung disease Diseases 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
206010029113 Neovascularisation Diseases 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
208000031481 Pathologic Constriction Diseases 0.000 description 2
206010034277 Pemphigoid Diseases 0.000 description 2
102000007982 Phosphoproteins Human genes 0.000 description 2
108010089430 Phosphoproteins Proteins 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
208000015634 Rectal Neoplasms Diseases 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
206010038933 Retinopathy of prematurity Diseases 0.000 description 2
241000220317 Rosa Species 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
208000000453 Skin Neoplasms Diseases 0.000 description 2
208000021712 Soft tissue sarcoma Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
108091008605 VEGF receptors Proteins 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
101150045355 akt1 gene Proteins 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
229940024606 amino acid Drugs 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000002491 angiogenic effect Effects 0.000 description 2
230000001772 anti-angiogenic effect Effects 0.000 description 2
230000001028 anti-proliverative effect Effects 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
230000031018 biological processes and functions Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
201000008275 breast carcinoma Diseases 0.000 description 2
150000001649 bromium compounds Chemical class 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
208000006990 cholangiocarcinoma Diseases 0.000 description 2
230000007882 cirrhosis Effects 0.000 description 2
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000012636 effector Substances 0.000 description 2
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
206010073096 invasive lobular breast carcinoma Diseases 0.000 description 2
150000004694 iodide salts Chemical class 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
208000002780 macular degeneration Diseases 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
201000003142 neovascular glaucoma Diseases 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
201000008968 osteosarcoma Diseases 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
239000000047 product Substances 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
208000005069 pulmonary fibrosis Diseases 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
108010014186 ras Proteins Proteins 0.000 description 2
206010038038 rectal cancer Diseases 0.000 description 2
201000001275 rectum cancer Diseases 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
201000009410 rhabdomyosarcoma Diseases 0.000 description 2
230000011664 signaling Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
201000000849 skin cancer Diseases 0.000 description 2
201000008261 skin carcinoma Diseases 0.000 description 2
208000000587 small cell lung carcinoma Diseases 0.000 description 2
239000002904 solvent Substances 0.000 description 2
206010041823 squamous cell carcinoma Diseases 0.000 description 2
230000036262 stenosis Effects 0.000 description 2
208000037804 stenosis Diseases 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
210000003954 umbilical cord Anatomy 0.000 description 2
201000005112 urinary bladder cancer Diseases 0.000 description 2
230000002792 vascular Effects 0.000 description 2
210000003556 vascular endothelial cell Anatomy 0.000 description 2
LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical class C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 1
UCOYIUOEXIYJFD-UHFFFAOYSA-N 2-[4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]guanidine Chemical compound C1=CC(NC(=N)N)=CC=C1N1C(C=2C=C3C(C4=CC=CC=C4C=C3)=CC=2)=CC(C(F)(F)F)=N1 UCOYIUOEXIYJFD-UHFFFAOYSA-N 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 1
PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 1
208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
101150107888 AKT2 gene Proteins 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
101150051155 Akt3 gene Proteins 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
102000009840 Angiopoietins Human genes 0.000 description 1
108010009906 Angiopoietins Proteins 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
206010060971 Astrocytoma malignant Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
241000589969 Borreliella burgdorferi Species 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
101100322915 Caenorhabditis elegans akt-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
208000003732 Cat-scratch disease Diseases 0.000 description 1
206010063094 Cerebral malaria Diseases 0.000 description 1
239000004381 Choline salt Substances 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
101100481404 Danio rerio tie1 gene Proteins 0.000 description 1
101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
206010012441 Dermatitis bullous Diseases 0.000 description 1
206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
208000006402 Ductal Carcinoma Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
206010063045 Effusion Diseases 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
206010014824 Endotoxic shock Diseases 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
206010015218 Erythema multiforme Diseases 0.000 description 1
208000002476 Falciparum Malaria Diseases 0.000 description 1
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
206010017982 Gastrointestinal necrosis Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
YSWHPLCDIMUKFE-QWRGUYRKSA-N Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YSWHPLCDIMUKFE-QWRGUYRKSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
206010018498 Goitre Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010019663 Hepatic failure Diseases 0.000 description 1
206010019728 Hepatitis alcoholic Diseases 0.000 description 1
208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 description 1
101000623857 Homo sapiens Serine/threonine-protein kinase mTOR Proteins 0.000 description 1
101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010051151 Hyperviscosity syndrome Diseases 0.000 description 1
206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000002979 Influenza in Birds Diseases 0.000 description 1
206010061252 Intraocular melanoma Diseases 0.000 description 1
206010023125 Jarisch-Herxheimer reaction Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
206010023330 Keloid scar Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
208000000265 Lobular Carcinoma Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 description 1
108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
206010025312 Lymphoma AIDS related Diseases 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
208000032271 Malignant tumor of penis Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
208000034762 Meningococcal Infections Diseases 0.000 description 1
206010027295 Menometrorrhagia Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
101100481410 Mus musculus Tek gene Proteins 0.000 description 1
101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
101150044441 PECAM1 gene Proteins 0.000 description 1
101150037263 PIP2 gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
241000700639 Parapoxvirus Species 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
206010034299 Penile cancer Diseases 0.000 description 1
240000007711 Peperomia pellucida Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
208000007641 Pinealoma Diseases 0.000 description 1
201000011336 Plasmodium falciparum malaria Diseases 0.000 description 1
108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
101710182846 Polyhedrin Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
208000037062 Polyps Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 description 1
108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 description 1
206010037423 Pulmonary oedema Diseases 0.000 description 1
239000012614 Q-Sepharose Substances 0.000 description 1
102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 description 1
208000019155 Radiation injury Diseases 0.000 description 1
206010038486 Renal neoplasms Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
206010061934 Salivary gland cancer Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
101710142052 Serine/threonine-protein kinase mTOR Proteins 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
102100024547 Tensin-1 Human genes 0.000 description 1
108010088950 Tensins Proteins 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
201000005485 Toxoplasmosis Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
241000589884 Treponema pallidum Species 0.000 description 1
241000223109 Trypanosoma cruzi Species 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
208000023915 Ureteral Neoplasms Diseases 0.000 description 1
206010046392 Ureteric cancer Diseases 0.000 description 1
206010046431 Urethral cancer Diseases 0.000 description 1
206010046458 Urethral neoplasms Diseases 0.000 description 1
201000005969 Uveal melanoma Diseases 0.000 description 1
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
206010047741 Vulval cancer Diseases 0.000 description 1
208000004354 Vulvar Neoplasms Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
206010064930 age-related macular degeneration Diseases 0.000 description 1
229940064582 akten Drugs 0.000 description 1
208000002353 alcoholic hepatitis Diseases 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000009285 allergic inflammation Effects 0.000 description 1
208000028004 allergic respiratory disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002547 anomalous effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
206010064097 avian influenza Diseases 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
206010006007 bone sarcoma Diseases 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
201000003714 breast lobular carcinoma Diseases 0.000 description 1
201000003848 bronchiolitis obliterans Diseases 0.000 description 1
208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
201000002143 bronchus adenoma Diseases 0.000 description 1
208000000594 bullous pemphigoid Diseases 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical class [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
208000003295 carpal tunnel syndrome Diseases 0.000 description 1
108020001778 catalytic domains Proteins 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
238000011072 cell harvest Methods 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
239000008004 cell lysis buffer Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000009087 cell motility Effects 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
230000017455 cell-cell adhesion Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
201000007335 cerebellar astrocytoma Diseases 0.000 description 1
208000030239 cerebral astrocytoma Diseases 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
235000019417 choline salt Nutrition 0.000 description 1
150000004777 chromones Chemical class 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
239000003245 coal Substances 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
239000000306 component Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
208000021921 corneal disease Diseases 0.000 description 1
201000000159 corneal neovascularization Diseases 0.000 description 1
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
125000006165 cyclic alkyl group Chemical group 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
XOVJAYNMQDTIJD-UHFFFAOYSA-N cyclopentobarbital Chemical compound C1CC=CC1C1(CC=C)C(=O)NC(=O)NC1=O XOVJAYNMQDTIJD-UHFFFAOYSA-N 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000030609 dephosphorylation Effects 0.000 description 1
238000006209 dephosphorylation reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
229950006137 dexfosfoserine Drugs 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
150000008050 dialkyl sulfates Chemical class 0.000 description 1
LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical class CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000005014 ectopic expression Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
230000010595 endothelial cell migration Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
208000024519 eye neoplasm Diseases 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
229960000556 fingolimod Drugs 0.000 description 1
SWZTYAVBMYWFGS-UHFFFAOYSA-N fingolimod hydrochloride Chemical compound Cl.CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 SWZTYAVBMYWFGS-UHFFFAOYSA-N 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
238000002875 fluorescence polarization Methods 0.000 description 1
238000002376 fluorescence recovery after photobleaching Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
230000001434 glomerular Effects 0.000 description 1
210000003904 glomerular cell Anatomy 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
210000003128 head Anatomy 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
230000036541 health Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
208000029824 high grade glioma Diseases 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000000521 hyperimmunizing effect Effects 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
201000010985 invasive ductal carcinoma Diseases 0.000 description 1
208000037906 ischaemic injury Diseases 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 1
LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical compound OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
210000000244 kidney pelvis Anatomy 0.000 description 1
206010023841 laryngeal neoplasm Diseases 0.000 description 1
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
231100000835 liver failure Toxicity 0.000 description 1
208000007903 liver failure Diseases 0.000 description 1
235000015250 liver sausages Nutrition 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
208000025036 lymphosarcoma Diseases 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
208000030883 malignant astrocytoma Diseases 0.000 description 1
201000011614 malignant glioma Diseases 0.000 description 1
208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
208000026037 malignant tumor of neck Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
108010082117 matrigel Proteins 0.000 description 1
210000000716 merkel cell Anatomy 0.000 description 1
210000003584 mesangial cell Anatomy 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
206010062198 microangiopathy Diseases 0.000 description 1
210000005063 microvascular endothelium Anatomy 0.000 description 1
210000004088 microvessel Anatomy 0.000 description 1
201000005962 mycosis fungoides Diseases 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical compound C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
201000002575 ocular melanoma Diseases 0.000 description 1
210000004248 oligodendroglia Anatomy 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
238000003566 phosphorylation assay Methods 0.000 description 1
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
229940075930 picrate Drugs 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
239000006187 pill Substances 0.000 description 1
208000024724 pineal body neoplasm Diseases 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
239000011505 plaster Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
206010035653 pneumoconiosis Diseases 0.000 description 1
208000030761 polycystic kidney disease Diseases 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical class [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
201000011461 pre-eclampsia Diseases 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
230000000861 pro-apoptotic effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
108010043671 prostatic acid phosphatase Proteins 0.000 description 1
208000005333 pulmonary edema Diseases 0.000 description 1
201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
238000007420 radioactive assay Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000009467 reduction Effects 0.000 description 1
201000007444 renal pelvis carcinoma Diseases 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
208000004644 retinal vein occlusion Diseases 0.000 description 1
210000001210 retinal vessel Anatomy 0.000 description 1
238000012552 review Methods 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
238000005488 sandblasting Methods 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
201000005671 spondyloarthropathy Diseases 0.000 description 1
210000004085 squamous epithelial cell Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000011541 total hip replacement Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000008733 trauma Effects 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
208000029584 urinary system neoplasm Diseases 0.000 description 1
208000037965 uterine sarcoma Diseases 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
201000005102 vulva cancer Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1
CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
229950009819 zotarolimus Drugs 0.000 description 1